David Eller is a graduate of Texas A&M University, the Stanford Graduate School of Business Executive Program, the Harvard Business School Advanced Management Program, and the Stanford Business School Corporate Governance Program.  He also served eight years as officer on active duty and reserves for the United States Army, Corps of Engineers.  He served as a Commanding Officer, 541^st Combat Engineer Company, 11^th Engineer Group, 7^th Army, Corps of Engineers – Schwetzingen, Germany.

Mr. Eller has a career in senior management which spans 35 years.  His positions during this time include President of DuPont Pharmaceuticals Company – Europe, Strategic Advisor to the Chief Operating Officer of the E. I. du Pont de Nemours and Company (“The DuPont Company”); Chief Executive Officer and President of Virbac Corporation; and Founder, Chairman, and Chief Executive Officer of Granada Biosciences, Inc.  Along with these prestigious positions, Mr. Eller has also provided consulting services to many public and privately held domestic and international corporations which operate in different industry sectors.  These industries range from life sciences and bioscience research and development to pharmaceutical manufacturing and distribution.

In addition to many positions in his senior management career, Mr. Eller has served two terms as Chairman of the Board of Regents of the Texas A&M University System, while concurrently serving as Chancellor of the Texas A&M University System for a short period.  During his tenure at Texas A&M University, Mr. Eller established the Institute of Biosciences and Technology, which is located in the Texas Medical Center.  He also established a number of additional bioscience programs which included establishing procedures for intellectual property commercialization.

Mr. Eller has served or is currently serving on many intellectual boards which include the Boards of Baylor College of Medicine, DuPont Pharmaceuticals Company – Europe, the Foundation for Biomedical Research, Rice University Energy & Environmental Systems Institute, Memorial Hermann Hospital, Texas Chamber of Commerce, Allied Bancshares, and First Interstate Bank, among others.

Mr. Eller has received a number of prestigious awards and honors including the Medallion of Entrepreneurship, Beta Gamma Sigma National Entrepreneur of the Year Award, the Ernst & Young Entrepreneur of the Year Award, and the Enterprise Award for his work in the biotechnology and life science fields.  He also received the Paul Harris Award from Rotary International and was the first person in the history of Texas A&M University to receive the title of Chairman Emeritus of the Texas A&M University System.  In his honor, the David G. Eller Oceanography and Meteorology Building at Texas A&M University was named after him.

Dr. Stanley Jones, M.D. is an orthopedic spine surgeon who has an active spine practice in the State of Texas, and is a board certified member of the American Board of Orthopedic Surgery.

Dr. Jones received a B.A. degree in chemistry from Texas Tech University and an M.D. degree from the University of Texas Southwestern Medical School. He completed an internship at the University of Utah and an orthopedic residency at the University of Texas Medical School in Houston. He then served in the U.S. Army as a Captain in the Medical Corp.

Dr. Jones has served as President of the International Intradiscal Therapy Society, President of the Texas Spine Society, and was previously a Director of Memorial Hermann Hospital Systems Spine Surgery program. He is an active member of the North American Spine Society and the American Academy of Orthopedic Surgery.

Dr. Jones’ current interests are in the field of minimally invasive spine surgery, pain management, and the use of adult autologous mesenchymal stem cells for medical benefits to patients.

In 2009, Dr. Jones suffered from a sudden onset of debilitating autoimmune psoriatic arthritis. Although he continued to see patients, his condition prevented him from performing surgery at his full capacity. He was forced to reduce his surgical load by 75%. Dr. Jones located a company in Seoul, South Korea, that had developed a state-of-the-art technology which allowed him to receive the treatment of his own stem cells. Four months after receiving his stem cells, he was able to return to a normal surgery schedule and a life without pain. Dr. Jones is responsible for bringing stem cell technology to Texas from overseas.

Ms. Ferrenz has more than 14 years of experience as a practicing attorney representing companies in health-related industries.  Her practice has focused on regulatory compliance and litigation, with expertise in FDA law, advertising law, administrative law, civil litigation and contract law. Before joining Celltex Ms. Ferrenz was a Principal with Emord & Associates, P.C. Ms. Ferrenz’s practice focus and personal interest in health products comes from her scientific background.  After receiving her Bachelor’s degree in Biology from University of Mary Washington, she worked first for the Institute for Genomic Research in Maryland and then for Washington D.C.’s Children’s National Medical Center in its Center for Cancer and Transplantation Biology.  Ms. Ferrenz graduated from George Washington University’s Law School and completed a legal internship with the U.S. Department of Health and Human Service’s Office of Research Integrity.

Ms. Lee has more than nine years of experience in biotechnology business development, including business expansion and strategic partnering. Currently, in her role at Celltex, Ms. Lee conducts physician training and education, supervises the banking process, forms alliances with industry academia and government and oversees marketing and sales. Previously, Ms. Lee  worked for the Maryland Department of Business and Economic Development, attracting life companies to the state.  She then moved to the private industry where she headed up regulatory activities, managed all marketing activities and facilitated research and partnering agreements. Ms. Lee graduated from University of Toronto with a degree in Bioethics and Human Biology. She received her M.S.c in Biotechnology with a concentration in Enterprise Development from Johns Hopkins University.

Mr. Mauzé has over 15 years of experience leading and growing organizations. His experience includes project management, account management and leadership roles in government organizations, healthcare start-ups, Fortune 500 companies and community organizations. He has focused his energies on bringing innovation to the health care marketplace with an eye towards health, wellness, and transforming the delivery of care by improving quality of life while reducing healthcare expenditures. Before joining Celltex Mr. Mauzé spent several years helping found and grow companies in the human and animal health space. Prior to that, Mr. Mauzé served at Walgreens’s Take Care Clinics as the Regional Vice President of Business Operations, as well as Vice President of Operations for Whole Health Management before its acquisition by Walgreens. He previously worked in the Office of Technology Commercialization at the Mayo Clinic and worked for Governor Rick Perry, current Governor of Texas. While in the Governor’s office, he worked directly with the Governor and his Chief of Staff on legislative and strategic initiatives. Additionally, Mr. Mauzé led the development and rollout of the first annual Governor’s fitness initiative to state agencies and Fortune 500 companies across the state. He received his BA in chemistry with a minor in business from Texas A&M University in College Station, Texas and his MBA from Harvard Business School with a focus on innovation in healthcare.

Hyeonggeun Park has over thirteen years of experience in biotechnology, particularly stem cell technology, tissue engineering and chemical engineering.  Mr. Park has a unique education including a Master’s Degree in Biotechnology, and a BS degree with a dual major in Biotechnology and Chemical Engineering from Ajou University in South Korea.  Mr. Park served as General Manager/Senior Research Engineer, GMP Manufacturing Department Head of RNL Bio Co., Ltd. Central Research Institute in Seoul, South Korea, for nine years.  During the course of his work he gained extensive experience in stem cell biology, the use of stem cells in therapeutic applications, including the use of stem cells (isolated from tissue and grown in culture) in development of tissue engineered products to make potential replacement tissues to treat injury or disease including cartilage tissue.  Mr. Park’s expertise in chemical engineering and his double major, when coupled with his stem cell biology, isolation and stem cell culturing expertise and tissue engineering experience is a very unique skill set.  He is an author on numerous publications describing the use of adipose stem cells, and his work directed toward the isolation and culture of mesenchymal stem cells derived from adipose tissue is recognized to be important in the field and highly original.  He developed a proprietary culture medium which supports the long term growth and expansion of adipose-derived stem cells at large scale.  Additionally, Mr. Park developed a large scale process for the required stem cell culture, which is groundbreaking work in this field.  Mr. Park is an inventor on a patent related to enhancing the stability of stem cells, which is a novel body of work with application in the fields of stem cells and commercial application of stem-cell based therapeutics and stem-cell-based tissue engineering products, and he is the author of five additional patents.  He has key skills in the area of cGTP (current Good Tissue Practice) and cGMP (current Good Manufacturing Practice) compliant manufacture and quality control, particularly as related to stem cells.

Dr. Young has over twenty years of clinical, laboratory, research, and product development experience. She has extensive academic experience in cell biology, molecular biology, protein science, biochemistry, and animal models. Prior to joining Celltex she served as the senior scientist and associate research scientist for PDD Inc., a leading global contract research organization, where she expanded her industry GMP experience doing drug analysis. Dr. Young has a track record of performing and leading projects in areas of genetic mutation and deletion analysis, molecular hematology, FISH probe design and analysis, recombinant protein and kinetics analysis, development and optimization of laboratory assays, cell sorting and flow cytometry analysis, drug trials and animal models. She has demonstrated her comprehensive knowledge through the two book chapters and twenty-five publications she has authored. Dr. Young graduated from Zhejiang University School of Medicine in China, and has practiced internal medicine for four years. She received her PhD in 1999 from Lund University, Sweden. Dr. Young completed a post-doctoral fellowship and served as a research specialist at the Howard Hughes Medical Institute, Department of Hematology and Medical Oncology.